Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1947 1
1949 2
1951 6
1952 5
1953 1
1954 4
1955 5
1956 1
1957 3
1958 3
1960 1
1961 1
1962 6
1963 1
1965 2
1966 2
1967 2
1968 3
1969 1
1971 2
1973 3
1974 4
1975 11
1976 8
1977 2
1978 5
1979 8
1980 4
1981 4
1982 1
1983 2
1984 2
1985 10
1986 6
1987 5
1988 10
1989 4
1990 9
1991 12
1992 3
1993 12
1994 8
1995 9
1996 11
1997 16
1998 12
1999 11
2000 9
2001 13
2002 14
2003 6
2004 16
2005 10
2006 15
2007 19
2008 21
2009 18
2010 14
2011 21
2012 17
2013 19
2014 26
2015 20
2016 18
2017 27
2018 30
2019 30
2020 40
2021 41
2022 33
2023 14

Text availability

Article attribute

Article type

Publication date

Search Results

669 results

Results by year

Filters applied: . Clear all
Page 1
PI3K/Akt signalling pathway and cancer.
Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. Fresno Vara JA, et al. Among authors: de castro j. Cancer Treat Rev. 2004 Apr;30(2):193-204. doi: 10.1016/j.ctrv.2003.07.007. Cancer Treat Rev. 2004. PMID: 15023437 Review.
Autoimmune pancreatitis - What we know and what do we have to know?
Qureshi A, Ghobrial Y, De Castro J, Siami-Namini K, Newman KA. Qureshi A, et al. Among authors: de castro j. Autoimmun Rev. 2021 Oct;20(10):102912. doi: 10.1016/j.autrev.2021.102912. Epub 2021 Jul 17. Autoimmun Rev. 2021. PMID: 34280553 Review. No abstract available.
Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function.
Yu G, Tzouvelekis A, Wang R, Herazo-Maya JD, Ibarra GH, Srivastava A, de Castro JPW, DeIuliis G, Ahangari F, Woolard T, Aurelien N, Arrojo E Drigo R, Gan Y, Graham M, Liu X, Homer RJ, Scanlan TS, Mannam P, Lee PJ, Herzog EL, Bianco AC, Kaminski N. Yu G, et al. Among authors: de castro jpw. Nat Med. 2018 Jan;24(1):39-49. doi: 10.1038/nm.4447. Epub 2017 Dec 4. Nat Med. 2018. PMID: 29200204 Free PMC article.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: de castro j. Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34839016 Free article. Clinical Trial.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Rosell R, et al. Among authors: de castro j. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285168 Clinical Trial.
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J. Novello S, et al. Among authors: de castro j. Ann Oncol. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121. Ann Oncol. 2018. PMID: 29668860 Free PMC article. Clinical Trial.
Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.
Mielgo-Rubio X, Martín M, Remon J, Higuera O, Calvo V, Jarabo JR, Conde E, Luna J, Provencio M, De Castro J, López-Ríos F, Hernando-Trancho F, Couñago F. Mielgo-Rubio X, et al. Among authors: de castro j. Future Oncol. 2021 Oct;17(30):4011-4025. doi: 10.2217/fon-2020-1255. Epub 2021 Aug 2. Future Oncol. 2021. PMID: 34337973 Review.
Oral Adult Rhabdomyoma.
da Silva Leonel ACL, Dos Santos ST, de Amorim Carvalho EJ, de Castro JFL, de Almeida OP, da Cruz Perez DE. da Silva Leonel ACL, et al. Among authors: de castro jfl. Head Neck Pathol. 2021 Dec;15(4):1253-1260. doi: 10.1007/s12105-021-01371-z. Epub 2021 Aug 10. Head Neck Pathol. 2021. PMID: 34378165 Free PMC article.
669 results